According to the FORMA THERAPEUTICS® website, Olutasidenib (FT-2102) is a next generation inhibitor of mutated isocitrate dehydrogenase 1 (IDH1m) intended to treat patients with relapsed/refractory acute myeloid leukemia (R/R AML) or myelodysplastic syndrome (MDS), and patients with glioma and other solid tumors with an IDH1 mutation.

IDH1 is a natural enzyme that is part of the normal metabolism of all cells. Mutations of IDH1 can produce excessive amounts of the oncometabolite 2-hydroxyglutarate (2-HG) which impairs cell differentiation and promotes blood malignancies and solid tumors.

More info on the FORMA THERAPEUTICS® website

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health